About

A Clear Focus on Eye Disorders

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

Targeting Front and Back of the Eye Indications

Our pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

Nyxol® Eye Drops

Nyxol is being developed for several indications including pharmacologically-induced mydriasis, presbyopia, and dim light or night vision disturbances.

Nyxol is an investigational 505(b)(2) product candidate that has been studied in over 650 subjects across 12 completed Phase 1, 2, and 3 trials.

See Nyxol Clearer

Our second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

APX3330 has been studied in over 340 patients across six Phase 1 and five Phase 2 trials.

See APX3330 Clearer

Clinical Trials with a Broad Range of View

Six clinical studies for ophthalmic indications have been launched since 2020, including VEGA-1 for presbyopia, MIRA-3 Phase 3 for reversal of pharmacologically-induced mydriasis (RM), MIRA-4 Pediatric trials for RM, and LYNX-1 Phase 3 for night (or dim light) vision disturbances (NVD). We have reported six positive readouts in four Phase 3 trials (MIRA-2, MIRA-3, MIRA-4 Pediatric trial, and LYNX-1) and two Phase 2 studies, VEGA-1 for Nyxol alone and Nyxol with Low Dose Pilocarpine (LDP), with an NDA filing for reversal of mydriasis (RM) coming soon.

View Our Trials

Aligning Our Vision with Partners

As part of our strategy, we continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets.

Partnership Opportunities

Leadership in Drug Development

Our leadership team is comprised of seasoned professionals with decades of experience in the pharmaceutical, biotech and medical research industries. Meet our teams.

Management Team Board of Directors Medical Advisory Board

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances